AAPL 228.6 0.4261% MSFT 412.7838 0.7404% NVDA 134.1695 3.3345% GOOGL 186.805 0.7904% GOOG 188.574 0.7663% AMZN 232.82 1.6016% META 715.35 0.1162% AVGO 235.392 4.6791% LLY 864.92 -1.5245% TSLA 358.0225 -0.9948% TSM 207.7 0.7665% V 351.34 0.954% JPM 271.4399 -1.5809% UNH 527.98 0.1803% NVO 83.95 -2.8581% WMT 102.26 1.0974% LVMUY 141.59 0.6826% XOM 110.81 1.7632% LVMHF 707.0 0.6105% MA 566.5 0.6664%
Last update at 2025-02-10T18:59:00Z
Eupraxia Pharmaceuticals Inc. Announces Appointment of Bruce Cousins as President & CFO
Mon 03 May 21, 11:00 AMBreakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Income before tax | -65.01200M | -76.24700M | -63.74500M | -166.37900M | -61.40000M |
Minority interest | - | - | - | - | - |
Net income | -69.45600M | -77.35100M | -65.21100M | -153.72300M | -57.10000M |
Selling general administrative | 17.83M | 17.14M | 14.72M | 17.73M | 16.00M |
Selling and marketing expenses | - | - | - | - | - |
Gross profit | 39.02M | 10.99M | -40.56700M | -51.59000M | -52.00000M |
Reconciled depreciation | 1.43M | 1.75M | 1.98M | 2.03M | 2.18M |
Ebit | -65.45600M | -73.52200M | -57.80600M | -144.07400M | -65.50000M |
Ebitda | -61.03100M | -71.52300M | -57.09500M | -89.55500M | -63.30000M |
Depreciation and amortization | 4.42M | 2.00M | 0.71M | 54.52M | 2.20M |
Non operating income net other | 2.17M | 0.13M | -1.92800M | 24.85M | 28.66M |
Operating income | -65.45600M | -73.52200M | -57.80600M | -144.07400M | -89.80000M |
Other operating expenses | 102.24M | 82.64M | 64.18M | 77.36M | 76.10M |
Interest expense | 1.73M | 2.86M | 4.01M | 2.11M | 0.20M |
Tax provision | 4.44M | - | 0.00000M | -12.65600M | -4.28200M |
Interest income | 2.19M | 0.13M | 0.74M | 2.11M | 3.05M |
Net interest income | 0.47M | -2.73000M | -3.27000M | 0.00300M | 2.82M |
Extraordinary items | - | - | - | - | - |
Non recurring | - | - | 0.06M | 72.76M | 19.61M |
Other items | - | - | - | - | - |
Income tax expense | 4.44M | 1.10M | 1.47M | -12.65600M | -4.30000M |
Total revenue | 39.02M | 10.99M | 6.91M | 6.01M | 5.90M |
Total operating expenses | 102.24M | 82.64M | 64.18M | 77.36M | 76.10M |
Cost of revenue | - | - | 47.48M | 57.60M | 57.90M |
Total other income expense net | 0.44M | -2.72500M | -5.93900M | -22.30500M | 6.00M |
Discontinued operations | - | - | - | - | - |
Net income from continuing ops | -69.45600M | -76.24700M | -63.74500M | -153.72300M | -57.06000M |
Net income applicable to common shares | -69.45600M | -88.38600M | -75.86800M | -329.74400M | -67.15100M |
Preferred stock and other adjustments | - | 12.14M | 12.12M | 11.15M | 10.09M |
Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
Total assets | 144.40M | 195.42M | 204.49M | 137.08M | 105.53M |
Intangible assets | - | - | - | - | - |
Earning assets | - | - | - | - | - |
Other current assets | 3.65M | 2.87M | 4.45M | 3.12M | 1.79M |
Total liab | 38.38M | 58.57M | 35.05M | 35.11M | 32.79M |
Total stockholder equity | 106.02M | 136.85M | 169.44M | 101.97M | 72.74M |
Deferred long term liab | - |